Assessment of Efficacy and Safety of Zagotenemab: Results From PERISCOPE-ALZ, a Phase 2 Study in Early Symptomatic Alzheimer Disease.
Adam S FleisherLeanne M MunsieDavid G S PerahiaScott W AndersenIxavier A HigginsPaula M HauckAlbert C LoJohn R SimsMiroslaw BrysMark Mintunnull nullPublished in: Neurology (2024)
This study provides Class II evidence that for patients with early symptomatic AD, zagotenemab does not slow clinical disease progression.